Risheen Suresh Reejhsinghani, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Reejhsinghani’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A129653 · Current
Licensed to practise in California · since 2014 · expires 2028-04-30 · Maharashtra University of Health Sciences, K.J. Somaiya Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$16,025
Medicare paid this office $16,025 for 149 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 33 | $5,464 | $137 |
| Long return visit (40+ min) | 32 | $3,942 | $110 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 43 | $306 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 16 | $158 | $10 |
Who their Medicare patients are
149 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 16% · Women 50% · Also on Medicaid 25% · Health risk score 2.07. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 44% · Atrial fibrillation 44% · Chronic kidney disease 39% · Diabetes 34% · Heart failure 34% · Depression 28% · Cancer 26% · COPD 21% · Stroke 11% · Dementia 10%.
The office billed $72,086, Medicare allowed $23,097 and paid $16,025; for 197 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 149 | 197 | 75 | 2.07 | $72,086 | $16,025 |
| 2023 | 320 | 492 | 75 | 2.01 | $193,849 | $44,186 |
| 2022 | 313 | 519 | 74 | 1.97 | $186,248 | $42,221 |
| 2021 | 545 | 853 | 73 | 1.94 | $224,928 | $43,334 |
| 2020 | 446 | 750 | 73 | 2.26 | $223,442 | $41,212 |
| 2019 | 413 | 791 | 74 | 2.19 | $195,439 | $54,784 |
| 2018 | 86 | 159 | 71 | 1.71 | $38,411 | $16,933 |
| 2017 | 60 | 95 | 73 | 2.00 | $7,875 | $1,839 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Long return visit (40+ min) | 89 | $13,825 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $7,131 | $110 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 52 | $6,218 | $120 |
| New patient visit (60+ min) | 19 | $2,985 | $157 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,879 | $160 |
| Long return visit (40+ min) | 18 | $2,753 | $153 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,499 | $107 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 40 | $957 | $24 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 19 | $631 | $33 |
| Telehealth originating site facility fee | 22 | $529 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 48 | $381 | $7 |
2022: 10 services
| Long return visit (40+ min) | 83 | $12,331 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $7,499 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 47 | $5,794 | $123 |
| Long return visit (40+ min) | 20 | $3,735 | $162 |
| New patient visit (60+ min) | 15 | $2,526 | $168 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 50 | $1,339 | $24 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,270 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $990 | $66 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 81 | $623 | $8 |
| Telehealth originating site facility fee | 21 | $550 | $22 |
2021: 12 services
| Long return visit (40+ min) | 67 | $11,101 | $131 |
| Long return visit (40+ min) | 20 | $4,207 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,105 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,289 | $126 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 294 | $2,806 | $8 |
| New patient visit (60+ min) | 13 | $2,540 | $195 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 73 | $1,748 | $23 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,659 | $92 |
| Telehealth originating site facility fee | 36 | $967 | $21 |
| Return visit (30+ min) | 18 | $939 | $52 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 18 | $285 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 18 | $192 | $11 |
2020: 12 services
| Long return visit (40+ min) | 36 | $4,641 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,217 | $96 |
| Return visit (30+ min) | 48 | $3,897 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,757 | $125 |
| Long return visit (40+ min) | 24 | $3,510 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,306 | $66 |
| New patient visit (60+ min) | 13 | $2,249 | $173 |
| Return visit (30+ min) | 25 | $2,189 | $78 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 210 | $1,792 | $8 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 69 | $1,739 | $24 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,038 | $69 |
| Telehealth originating site facility fee | 31 | $885 | $22 |
2019: 15 services
| Long return visit (40+ min) | 57 | $8,681 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $7,268 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,775 | $184 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,963 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $3,501 | $66 |
| Return visit (30+ min) | 43 | $3,231 | $67 |
| Long return visit (40+ min) | 26 | $2,880 | $85 |
| New patient visit (60+ min) | 18 | $2,596 | $144 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,282 | $99 |
| Return visit (30+ min) | 23 | $2,174 | $70 |
| New patient visit (45+ min) | 17 | $1,867 | $110 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 65 | $1,865 | $25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 175 | $1,428 | $8 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,091 | $91 |
| Hospital observation care on day of discharge | 12 | $811 | $68 |
2018: 5 services
| New patient visit (60+ min) | 22 | $3,311 | $151 |
| Long return visit (40+ min) | 18 | $2,294 | $100 |
| New patient visit (60+ min) | 15 | $2,185 | $146 |
| New patient visit (45+ min) | 18 | $2,075 | $115 |
| Return visit (30+ min) | 12 | $777 | $65 |
2017: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 41 | $399 | $7 |
Medicaid work
$3,000 in 2024
Medicaid paid $3,000 for 67 billed services this clinician did in 2024, up to 41 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 24 | $2,475 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 43 | $525 |
| 2024 | 67 | 2 | 41 | $3,000 |
| 2023 | 103 | 2 | 37 | $4,829 |
| 2022 | 140 | 2 | 29 | $7,901 |
| 2021 | 351 | 2 | 87 | $5,914 |
| 2020 | 196 | 1 | 63 | $2,225 |
| 2019 | 127 | 2 | 46 | $1,993 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 66 | $4,340 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 37 | $489 |
2022
| Long return visit (40+ min) | 98 | $7,373 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 42 | $528 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 312 | $3,616 |
| Long return visit (40+ min) | 39 | $2,298 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 196 | $2,225 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 115 | $1,392 |
| Long return visit (40+ min) | 12 | $601 |
Drugs they prescribed that Part D paid
$143,973
Pharmacies billed $143,973 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,050) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
945 generic and 105 brand-name prescriptions · $143,973 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 61 | $85,734 | $1,405 |
| Rosuvastatin | 109 | $2,358 | $22 |
| Metoprolol | 131 | $2,338 | $18 |
| Ezetimibe | 56 | $1,466 | $26 |
| Carvedilol | 61 | $1,116 | $18 |
See all 16 drugs
| Eliquis | 61 | $85,734 | $1,405 |
| Rosuvastatin | 109 | $2,358 | $22 |
| Metoprolol | 131 | $2,338 | $18 |
| Ezetimibe | 56 | $1,466 | $26 |
| Carvedilol | 61 | $1,116 | $18 |
| Atorvastatin | 98 | $1,083 | $11 |
| Amlodipine Besylate | 105 | $978 | $9 |
| Losartan | 67 | $593 | $9 |
| Furosemide | 80 | $566 | $7 |
| Clopidogrel | 34 | $532 | $16 |
| Hydralazine | 15 | $357 | $24 |
| Diltiazem 24hr Er (Cd) | 12 | $291 | $24 |
| Lisinopril | 19 | $207 | $11 |
| Spironolactone | 15 | $169 | $11 |
| Nitroglycerin | 13 | $123 | $9 |
| Metoprolol | 14 | $104 | $7 |
Year by year
| 2024 | 1,050 | 146 | 0% (0) | 10% | $143,973 |
| 2023 | 1,247 | 164 | 0% (0) | 9% | $157,499 |
| 2022 | 1,151 | 155 | 0% (0) | 10% | $118,781 |
| 2021 | 1,015 | 128 | 0% (0) | 8% | $84,961 |
| 2020 | 1,030 | 136 | 0% (0) | 11% | $70,177 |
| 2019 | 860 | 145 | 0% (0) | 12% | $54,142 |
| 2018 | 218 | 54 | 0% (0) | 16% | $12,830 |
| 2017 | 12 | None | 0% (0) | None | $307 |
| 2016 | 36 | None | 0% (0) | None | $507 |
| 2015 | 22 | None | 0% (0) | 0% | $412 |
| 2014 | 52 | 13 | 0% (0) | 27% | $3,991 |
| 2013 | 65 | 19 | 0% (0) | 25% | $4,138 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Eliquis | 43 | $65,110 | $1,514 |
| Jardiance | 18 | $20,664 | $1,148 |
| Repatha Sureclick | 11 | $6,552 | $596 |
| Ezetimibe | 50 | $3,976 | $80 |
| Metoprolol | 173 | $3,661 | $21 |
| Rosuvastatin | 107 | $3,317 | $31 |
| Atorvastatin | 154 | $2,824 | $18 |
| Amlodipine Besylate | 146 | $2,327 | $16 |
| Losartan | 72 | $1,620 | $23 |
| Carvedilol | 78 | $1,537 | $20 |
| Nebivolol | 14 | $1,500 | $107 |
| Potassium Chloride | 17 | $713 | $42 |
| Clopidogrel | 33 | $681 | $21 |
| Isosorbide Mononitrate Er | 15 | $630 | $42 |
| Furosemide | 72 | $548 | $8 |
| Valsartan | 12 | $441 | $37 |
| Lisinopril | 30 | $437 | $15 |
| Spironolactone | 13 | $294 | $23 |
| Metoprolol | 11 | $105 | $10 |
2022: 15 drugs
| Eliquis | 44 | $52,893 | $1,202 |
| Repatha Sureclick | 14 | $9,830 | $702 |
| Ezetimibe | 43 | $4,154 | $97 |
| Rosuvastatin | 104 | $3,903 | $38 |
| Metoprolol | 149 | $2,989 | $20 |
| Atorvastatin | 154 | $2,335 | $15 |
| Carvedilol | 96 | $1,653 | $17 |
| Losartan | 63 | $1,086 | $17 |
| Amlodipine Besylate | 118 | $1,011 | $9 |
| Hydralazine | 21 | $976 | $46 |
| Clopidogrel | 36 | $733 | $20 |
| Enalapril Maleate | 13 | $417 | $32 |
| Lisinopril | 29 | $396 | $14 |
| Furosemide | 42 | $272 | $6 |
| Atenolol | 12 | $19 | $2 |
2021: 17 drugs
| Eliquis | 23 | $25,232 | $1,097 |
| Xarelto | 17 | $17,845 | $1,050 |
| Repatha Sureclick | 15 | $10,630 | $709 |
| Rosuvastatin | 109 | $4,867 | $45 |
| Metoprolol | 147 | $2,885 | $20 |
| Atorvastatin | 137 | $1,957 | $14 |
| Ezetimibe | 28 | $1,577 | $56 |
| Carvedilol | 70 | $1,347 | $19 |
| Amlodipine Besylate | 107 | $1,070 | $10 |
| Hydralazine | 31 | $754 | $24 |
| Losartan | 42 | $655 | $16 |
| Isosorbide Mononitrate Er | 20 | $631 | $32 |
| Clopidogrel | 33 | $581 | $18 |
| Lisinopril | 54 | $503 | $9 |
| Furosemide | 24 | $145 | $6 |
| Spironolactone | 16 | $102 | $6 |
| Hydrochlorothiazide | 12 | $45 | $4 |
2020: 17 drugs
| Xarelto | 21 | $20,355 | $969 |
| Eliquis | 18 | $13,248 | $736 |
| Rosuvastatin | 102 | $3,897 | $38 |
| Metoprolol | 125 | $2,658 | $21 |
| Atorvastatin | 136 | $2,441 | $18 |
| Ezetimibe | 22 | $1,137 | $52 |
| Carvedilol | 98 | $1,122 | $11 |
| Amlodipine Besylate | 87 | $797 | $9 |
| Isosorbide Mononitrate Er | 36 | $793 | $22 |
| Losartan | 46 | $760 | $17 |
| Potassium Chloride | 12 | $684 | $57 |
| Lisinopril | 59 | $483 | $8 |
| Clopidogrel | 41 | $457 | $11 |
| Furosemide | 31 | $218 | $7 |
| Spironolactone | 15 | $171 | $11 |
| Hydrochlorothiazide | 12 | $76 | $6 |
| Metoprolol | 21 | $76 | $4 |
2019: 15 drugs
| Xarelto | 17 | $18,864 | $1,110 |
| Eliquis | 16 | $8,104 | $506 |
| Atorvastatin | 147 | $2,793 | $19 |
| Metoprolol | 93 | $2,018 | $22 |
| Rosuvastatin | 77 | $1,996 | $26 |
| Carvedilol | 89 | $1,170 | $13 |
| Lisinopril | 67 | $628 | $9 |
| Potassium Chloride | 14 | $575 | $41 |
| Amlodipine Besylate | 66 | $519 | $8 |
| Losartan | 40 | $426 | $11 |
| Isosorbide Mononitrate Er | 20 | $302 | $15 |
| Furosemide | 38 | $239 | $6 |
| Clopidogrel | 16 | $150 | $9 |
| Metoprolol | 19 | $116 | $6 |
| Spironolactone | 13 | $113 | $9 |
2018: 7 drugs
| Atorvastatin | 39 | $766 | $20 |
| Metoprolol | 28 | $398 | $14 |
| Carvedilol | 16 | $164 | $10 |
| Losartan | 11 | $75 | $7 |
| Lisinopril | 17 | $58 | $3 |
| Amlodipine Besylate | 15 | $53 | $4 |
| Furosemide | 15 | $50 | $3 |
2014: 2 drugs
| Metoprolol | 11 | $808 | $73 |
| Atorvastatin | 11 | $710 | $65 |
2013: 1 drug
| Metoprolol | 19 | $837 | $44 |
Money from drug and device companies
$117 in 2019
A payment is not proof that care is biased.
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $117 | 1 payment
|
See the published payment
| Abbott Laboratories | Meals · 2019-07-02 | Heartmate 3 Left Ventricular Dev | $117 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508012154
- Licence
- CA A129653, MA 237107California A129653: Current · expires 2028-04-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X); Federal specialty code 207UN0901X (207UN0901X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-08-14
- NPI last updated
- 2024-04-24
- NPI record certified
- 2024-04-24
This is when the NPI record was last certified, not a medical board exam.